In TPC-1 thyroid carcinoma cells, 20 nM Ro 61-8048 reduced CCK-8 cell survival in the SERINC2-knockdown condition; the vector-control comparison was nonsignificant. This combination experiment does not establish an apoptosis-specific endpoint or formal synergy. [2]
Cellular effects depend on the experimental context. In HEK293 cells engineered to overexpress human KMO, 20 μM Ro61-8048 during a 24 h, 500 μM 3-hydroxykynurenine challenge reversed the protection associated with KMO overexpression, as assessed by mitochondrial potential, LDH release and caspase-3/7 activity. [3]
Human KMO activity inhibition assay
Biochemical assay · Cell-free human KMO activity assay; NADPH absorbance readout [1]
Ro 61-8048 served as the reference inhibitor in a duplicate human KMO enzyme assay. The reported IC50 was 5.1 μM. This is an assay-specific activity endpoint, not a cellular treatment concentration or a universal potency value.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 3C caption: 2–10 μM
- Exposure duration
- 1.5 h
- Method
- Cell-free enzyme reaction at room temperature
- Vehicle
- DMSO stock; final DMSO fraction for the Ro concentration series is not specified
- Reported limits
- Blank/control absorbances are explicit in equation 1; their detailed compositions and IC50 uncertainty are not specified. The substrate mixture description does not unambiguously establish final kynurenine/NADPH concentrations; no final concentrations are reconstructed.
Methods and source locations
Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048
Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.
Sections 2.1 and 2.4; equation 1; section 3.2; Figure 3C; Table 2, Ro 61-8048 row
Inhibition of human KMO activity: Absorbance at 340 nm after 1.5 h; activity normalized using sample, blank and control absorbances (equation 1); GraphPad Prism fit. Assay performed in duplicate. — Sections 2.1 and 2.4; equation 1; section 3.2; Figure 3C; Table 2, Ro 61-8048 row
Binding to immobilized recombinant human KMO
Biochemical assay · Recombinant human KMO immobilized on a CM5 SPR chip [1]
Ro 61-8048 showed concentration-dependent SPR responses with a reported equilibrium dissociation constant of 1.1 × 10−5 M. Binding affinity is distinct from the enzyme-inhibition IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- Methods: 1.25–20 μM; Figure 6B labels: 1, 3, 10 and 20 μM
- Exposure duration
- 60 s association and 60 s dissociation per cycle
- Method
- Surface plasmon resonance; 100 μL/min sample flow
- Vehicle
- HBS-P+ running buffer with 3% DMSO
- Reported limits
- Number of independent SPR runs and uncertainty of KD are not specified. Rounded figure labels differ from the stated lower end of the preparation range; these are retained as reported.
Methods and source locations
Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048
Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.
Sections 2.1, 2.6–2.7 and 3.4; Figure 5 caption; Figure 6B; Table 4, Ro 61-8048 row
Binding to recombinant human KMO: Biacore T200; reference flow cell with blank immobilization and DMSO solvent correction; binding parameters in Table 4. — Sections 2.1, 2.6–2.7 and 3.4; Figure 5 caption; Figure 6B; Table 4, Ro 61-8048 row
TPC-1 viability with SERINC2 knockdown and Ro 61-8048
Cell-based study · Human TPC-1 papillary thyroid carcinoma cells transfected with SERINC2 shRNA or vector control [2]
In the factorial vector/shRNA experiment, Ro 61-8048 at 20 nM reduced CCK-8 cell survival in SERINC2-knockdown cells relative to their DMSO condition. The vector-control comparison is marked nonsignificant. No exact bar heights are extracted.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 nM
- Exposure duration
- Caption states drug treatment after 24 h shRNA transfection; subsequent drug exposure duration is not specified
- Method
- CCK-8 viability assay; shared method measures absorbance at 450 nm
- Vehicle
- DMSO; final fraction not specified
- Co-treatment
- SERINC2 shRNA; vector and DMSO conditions are shown. Alizarin is a separate comparator, not a stated co-treatment with Ro 61-8048.
- Reported limits
- Figure 6 caption reports mean ± SEM, whereas section 2.10 generally states mean ± SD of at least three experiments. Exact n and drug exposure time for panel F are not specified. No apoptosis-specific drug endpoint or formal synergy estimate is adopted.
Methods and source locations
Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048
Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.
Sections 2.3–2.5 and 2.10; section 3.4; Figure 6F and caption
CCK-8 cell survival with vector or SERINC2 shRNA: CCK-8 viability readout, Figure 6F; figure reports mean ± SEM and significance symbols; no exact n is attached to panel F. — Sections 2.3–2.5 and 2.10; section 3.4; Figure 6F and caption
Reversal of protection from 3-hydroxykynurenine injury
Cell-based study · Wild-type HEK293 versus HEK293 cells stably overexpressing human KMO(V5-6His) [3]
KMO-overexpressing cells were less susceptible to 500 μM 3-hydroxykynurenine (3HK). Co-treatment with 20 μM Ro61-8048 reversed this protection, with changes in mitochondrial membrane potential, LDH release and caspase-3/7 activity. This is a limiting, model-specific result rather than evidence that KMO inhibition is uniformly cytoprotective.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 μM Ro61-8048
- Exposure duration
- 24 h
- Method
- Parallel JC-1, LDH and caspase-3/7 assays under the same factorial challenge conditions
- Co-treatment
- 500 μM 3HK; both cell types also have medium-only, Ro61-8048-only and 3HK-only controls
- Reported limits
- Ro61-8048 solvent/final vehicle concentration is not specified in the relevant assay methods. Methods describe triplicate treatment; caption gives n=6 per condition and three independent experiments. These statements are preserved without redefining n.
Methods and source locations
Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048
Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.
Results: KMO-overexpressing cells are protected from 3HK-mediated toxicity as a function of KMO activity; Figure 3a–c/caption; Methods: JC-1, LDH and caspase-3/7 assays
3HK-associated mitochondrial dysfunction, LDH release and caspase-3/7 activity: JC-1 red:green fluorescence ratio, supernatant LDH assay and caspase-3/7 luminescence; Figure 3a–c. Caption: n=6 per cell type/condition, SEM error bars; representative of three independent experiments. — Results: KMO-overexpressing cells are protected from 3HK-mediated toxicity as a function of KMO activity; Figure 3a–c/caption; Methods: JC-1, LDH and caspase-3/7 assays